MX2007004277A - Compuestos para la produccion de imagenes por perfusion miocardial. - Google Patents

Compuestos para la produccion de imagenes por perfusion miocardial.

Info

Publication number
MX2007004277A
MX2007004277A MX2007004277A MX2007004277A MX2007004277A MX 2007004277 A MX2007004277 A MX 2007004277A MX 2007004277 A MX2007004277 A MX 2007004277A MX 2007004277 A MX2007004277 A MX 2007004277A MX 2007004277 A MX2007004277 A MX 2007004277A
Authority
MX
Mexico
Prior art keywords
compounds
myocardial perfusion
perfusion imaging
imaging
myocardial
Prior art date
Application number
MX2007004277A
Other languages
English (en)
Inventor
David S Casebier
Ajay Purohit
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of MX2007004277A publication Critical patent/MX2007004277A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
    • H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic Table or AIIIBV compounds with or without impurities, e.g. doping materials
    • H01L21/30—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26
    • H01L21/31—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26 to form insulating layers thereon, e.g. for masking or by using photolithographic techniques; After treatment of these layers; Selection of materials for these layers
    • H01L21/3205—Deposition of non-insulating-, e.g. conductive- or resistive-, layers on insulating layers; After-treatment of these layers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Manufacturing & Machinery (AREA)
  • General Physics & Mathematics (AREA)
  • Power Engineering (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Computer Hardware Design (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

La presente descripcion esta dirigida a los compuestos que comprenden fracciones de produccion de imagenes y su uso para diagnosticar ciertos desordenes.
MX2007004277A 2004-10-18 2005-10-11 Compuestos para la produccion de imagenes por perfusion miocardial. MX2007004277A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61967804P 2004-10-18 2004-10-18
PCT/US2005/036275 WO2006044280A1 (en) 2004-10-18 2005-10-11 Compounds for myocardial perfusion imaging

Publications (1)

Publication Number Publication Date
MX2007004277A true MX2007004277A (es) 2007-05-16

Family

ID=36203281

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004277A MX2007004277A (es) 2004-10-18 2005-10-11 Compuestos para la produccion de imagenes por perfusion miocardial.

Country Status (14)

Country Link
US (1) US20060083681A1 (es)
EP (1) EP1803150A1 (es)
JP (1) JP2008517910A (es)
KR (1) KR20070070176A (es)
CN (1) CN101044606A (es)
AU (1) AU2005295952A1 (es)
CA (1) CA2584420A1 (es)
IL (1) IL182313A0 (es)
MX (1) MX2007004277A (es)
NO (1) NO20071613L (es)
RU (1) RU2007118548A (es)
TW (1) TW200628171A (es)
WO (1) WO2006044280A1 (es)
ZA (1) ZA200702843B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
EP1754484A1 (en) * 2005-08-17 2007-02-21 Dan Stoicescu Condensed pyrimidine derivatives as inhibitors of foic acid-dependent enzymes
AU2007339954B2 (en) * 2006-12-26 2013-06-20 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation
EP1958632A1 (en) * 2007-02-14 2008-08-20 Dan Stoicescu Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases
CA2967254C (en) 2008-02-29 2019-03-26 Lantheus Medical Imaging, Inc. Contrast agents for applications including imaging cancer
DK2419096T3 (da) 2009-04-15 2020-02-03 Lantheus Medical Imaging Inc Stabilisering af radiofarmaceutiske sammensætninger under anvendelse af ascorbinsyre
CN113058046A (zh) 2010-02-08 2021-07-02 兰休斯医疗成像公司 用于合成显像剂和其中间体的方法和装置
BR122020018186B1 (pt) 2010-05-11 2021-07-27 Lantheus Medical Imaging, Inc Uso de agentes de imagiologia para preparação de uma composição para detecção do transportador de norepinefrina (net) e método para a detecção de net
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765971A (en) * 1985-05-31 1988-08-23 Mallinckrodt, Inc. Technetium (Tc-99m)-arene complexes useful in myocardial imaging
WO1987002893A1 (en) * 1985-11-18 1987-05-21 Board Of Regents, The University Of Texas System Polychelating agents for image and spectral enhancement (and spectral shift)
US5567411A (en) * 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
US5252317A (en) * 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) * 1989-10-23 1989-12-13 Salutar Inc Compounds
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5679810A (en) * 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5760191A (en) * 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
US5417959A (en) * 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
US5801228A (en) * 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
US5804161A (en) * 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6403054B1 (en) * 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
IL142958A0 (en) * 1998-12-18 2002-04-21 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US20030044354A1 (en) * 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release

Also Published As

Publication number Publication date
JP2008517910A (ja) 2008-05-29
AU2005295952A1 (en) 2006-04-27
KR20070070176A (ko) 2007-07-03
CN101044606A (zh) 2007-09-26
WO2006044280A1 (en) 2006-04-27
EP1803150A1 (en) 2007-07-04
IL182313A0 (en) 2007-07-24
ZA200702843B (en) 2008-08-27
TW200628171A (en) 2006-08-16
RU2007118548A (ru) 2008-11-27
NO20071613L (no) 2007-04-25
US20060083681A1 (en) 2006-04-20
CA2584420A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
TW200628171A (en) Compounds for myocardial perfusion imaging
IL243840A0 (en) Contrast agents for myocardial perfusion imaging
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
JP2008501714A5 (es)
IL178911A0 (en) Contrast agents for myocardial perfusion imaging
NO20074544L (no) Inhibering av HER2-losriving med matriksmetalloproteaseantagonister
TW200626068A (en) Active compounds for seed treatment
PL1951227T3 (pl) Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca
IL186374A0 (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
HK1145316A1 (zh) 用於中樞神經系統疾病或腫瘤的成像、診斷和/或治療的化合物
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
MX2010000997A (es) Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b).
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
MX2008001638A (es) Metodo de espaciado de piel entumecida.
GB0606015D0 (en) therapeutic agents
MX2008001269A (es) Sistema de higiene.
GB0515325D0 (en) Improvements relating to the detection of lower limb disease
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
IL186286A0 (en) Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
TW200744645A (en) Contrast agents for myocardium perfusion imaging
MY150436A (en) 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
EP1796703A4 (en) COMPOSITION WITHOUT EXCIPIENT FOR THE TREATMENT OF ONYCHOMYCOSIS
RU2004132147A (ru) Адаптоген
ITTV20050186A1 (it) Lettino per l'abbronzatura del corpo.
ITVR20050093A1 (it) Iniettore particolarmente conformato da utilizzare preferibilmente ma non limitatamente per il consolidamento e l'impermeabilizzazione di murature e procedimento per il suo utilizzo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal